Press Releases for ACL

Press Releases
NovaBay Pharmaceuticals Reports Third Quarter Financials and Provides Update on Pipeline of Anti-Infective Compounds
Alcon Posts 5.9 Percent Sales Growth for Third Quarter
Synergetics USA, Inc. Announces Stay of Alcon Patent and Trademark Infringement Lawsuit
NovaBay Pharmaceuticals Announces the Closing of Its $2.45 Million Registered Direct Offering of Common Stock and Warrants
NovaBay Pharmaceuticals, Inc. Announces Pricing of Registered Direct Offering of Common Stock and Warrants
NovaBay Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results
NovaBay(R) Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference
Alcon Reports Solid Financial Results for Second Quarter
Alcon and AstraZeneca to Collaborate on Eye Drug Development
Alcon Commences Phase 2 Clinical Trial of NovaBay’s NVC-422 for Viral Conjunctivitis
Alcon Commences Phase 2 Clinical Trial of NovaBay's NVC-422 for Viral Conjunctivitis
Alcon Discontinues Development of Anecortave Acetate for Intraocular Pressure Reduction
Alcon Announces Second Quarter 2009 Financial Release and Conference Call Dates
Anthony Clark – Financial Results Highlights for Year Ended March 31, 2009
wRatings and UTEK Corporation's Strategos Identify Most Competitive Health Care Companies
wRatings and UTEK Corporation’s Strategos Identify Most Competitive Health Care Companies
wRatings and UTEK Corporation's Strategos Identify Most Competitive Health Care Companies
Alcon Breaks Ground in Singapore on First Asian Pharmaceutical Manufacturing Plant
Alcon Achieves Required Ownership in WaveLight AG to Initiate Squeeze-out
Abbreviated New Drug Application for Fondaparinux Accepted by US Food and Drug Administration
Alcon Shareholders Approve Dividend Increase and Elect New Members to the Board
Alcon Reports Rise in First Quarter Earnings on Organic Sales Growth
Alcon Research Institute Awards Six Top Scientists with Unrestricted Grants for Research on Eye Disease
Alcon Announces First Quarter 2009 Financial Release and Conference Call Dates
Alcon and the Asthma and Allergy Foundation of America Team Up to Educate Patients - Mar 27 2009 12:17AM
Alcon Files Form 20-F with U.S. Securities and Exchange Commission
Alcon Launches Website for PATANASE® Nasal Spray
Alcon Signs Contract with LCA-Vision for 75 ALLEGRETTO WAVE® Excimer Lasers
NovaBay Pharmaceuticals Announces Lead Anti-infective Product Candidate, NVC-422, Shown to be Effective in Treating Topical Fungal Infection
New AcrySof® IQ Toric IOL Approved for U.S. Patients with Cataracts and Astigmatism
Eye Disease Experts Present New Research on Vision
Alcon Fourth Quarter Diluted EPS Increased 12.8 Percent
Alcon Placed for the 11th Consecutive Year on FORTUNE Magazine’s List of ‘100 Best Companies to Work For’
BenchmarkJournal.Com (Complimentary) Analyst Review for DO, GR, ZMH and ACL
Kevin Buehler Appointed President and CEO of Alcon; Cary Rayment to Continue as Chairman of the Board
Alcon Announces Fourth Quarter 2008 Financial Release and Conference Call Dates
FDA Approves Alcon’s AcrySof® IQ ReSTOR® +3.0 D Intraocular Lens
Significant Milestone on Path to Commercialisation of Fondaparinux
Alcon Announces AZARGA® Ophthalmic Suspension Approved for Treatment of Patients with Glaucoma or Ocular Hypertension in the European Union
Key Fondaparinux Patent Allowed by U.S. Patent Office
Alcon Announces Two Agreements Designed to Expand Its Future Drug Portfolio
Alcon Announces Third Quarter 2008 Financial Release and Conference Call Dates
Alcon Plans to Expand Manufacturing Facility in West Virginia
Alcon Launches New AcrySof(R) ReSTOR(R) Intraocular Lens for Presbyopia Outside the U.S.
Alcon Expands Refractive Surgery Options with the Introduction of the AcrySof(R) Phakic Intraocular Lens Outside the U.S.
Alcon Plans to Repurchase Up to One Million Shares
ORBIS and Alcon Train China's Next Generation of Sight-Savers
CORRECTING and REPLACING The Alcon Research Institute Recognizes Seven Top Researchers in Ophthalmology with Unrestricted Grants
The Alcon Research Institute Recognizes Seven Top Researchers in Ophthalmology with Unrestricted Grants
Zacks Analyst Blog Highlights: Honda Motor Company Ltd., Eli Lilly and Co., Juniper Networks, Inc., Cisco Systems Inc. And Alcon Inc.
Alcon's Second Quarter Sales Rise 17.9 Percent; Net Earnings Increase 26.3 Percent
Alcon Enters Into Patent Cross-Licensing Agreement With AMO
Alchemia Patents Granted for Generic Fondaparinux
Alcon Announces Second Quarter 2008 Financial Release and Conference Call Dates
BeaconEquity.com Issues TraderNotes on Medical Instruments and Supplies Stocks: LLSR, EMITF, BLTI, OISI, ACL, LMNX, MELA, PMII
Alcon Shareholders Approve Increased Dividend and Elect New Members to the Board - Jun 1 2008 6:30AM
Alcon's First Quarter Sales Rise 16.2 Percent; Net Income Increases 24.0 Percent
Alcon's PATANASE(R) Nasal Spray Approved by FDA for Treatment of Nasal Allergy Symptoms
Alcon Announces Plans to Build Pharmaceutical Manufacturing Plant in Singapore
Novartis to Acquire 25 Percent Minority Stake in Alcon from Nestle